Firma Clinical Research — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Firma Clinical Research is a US-based, privately-held specialty CRO founded in 2005, specializing in decentralized clinical trial (DCT) execution and functional service provider (FSP) engagements for data services. The company's primary offering is its global home trial services, which facilitate in-home patient visits across 70+ countries to improve recruitment, diversity, and retention. It complements this with a strong biometrics team for biostatistics, programming, and data management, presenting itself as a nimble, expert-led alternative to large, full-service CROs.

Clinical ResearchDrug Development

Technology Platform

Integrated operational platform for decentralized clinical trials, combining a global network of home healthcare providers for in-home visits with specialized biostatistics and data management teams, delivered via a flexible Functional Service Provider (FSP) model.

Opportunities

The rapid adoption of decentralized and hybrid clinical trial models creates a large, growing market for expert execution.

Increasing regulatory and social emphasis on improving diversity and equity in clinical trials aligns perfectly with Firma's home-based service model, which reduces geographic and socioeconomic barriers to participation.

Risk Factors

Operational risk is high due to the complexity of managing a global network of home healthcare providers and ensuring protocol compliance outside traditional sites.

Intense competition from both large, full-service CROs building DCT capabilities and other niche providers threatens market share and pricing power.

Competitive Landscape

Firma competes in the crowded Contract Research Organization (CRO) market, differentiated as a boutique specialist in decentralized trial execution and biometrics. It faces competition from large, full-service CROs (e.g., IQVIA, PPD, Parexel) and other niche DCT-focused service providers. Its key competitive advantages are its focused expertise, flexible FSP model, and established global home visit network.

More companies in Digital Health & Biotech SaaS →More companies in United States →